PegIntron (Peginterferon alfa-2b) Injection, Powder for Solution for Subcutaneous Use

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

September 2015

Summary View

Drug Interactions

  • *update with data from CYP-enzyme studies, based on study report P392


December 2011

Summary View 


Neuropsychiatric Events
  • PegIntron should be used with caution in patients with a history of psychiatric disorders. Treatment with interferons may be associated with exacerbated symptoms of psychiatric disorders in patients with co-occurring psychiatric and substance use disorders. If treatment with interferons is initiated in patients with prior history or existence of psychiatric condition or with a history of substance use disorders, treatment considerations should include the need for drug screening and periodic health evaluation, including psychiatric symptom monitoring. Early intervention for re-emergence or development of neuropsychiatric symptoms and substance use is recommended.


Page Last Updated: 10/09/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.